What is claimed is:

1. A compound of formula (I)



(I)

wherein,

R^1 and R^2 are the same or are different and are C_{1-8}alkyl, C_{2-8}alkylene, C_{3-8}cycloalkyl, aryl, heteroaryl, heterocycloalkyl, C_{3-6}cycloalkylaryl, or heterocycloaryl; wherein said alkyl, alkylene, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkylaryl, or heterocycloaryl are unsubstituted or substituted by one or more groups selected from the group consisting of halogen, C_{1-8}alkyl, C_{1-8}alkoxy, C_{1-8}thioalkoxy, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, CF_3, SCF_3, $NHC(O)_nR^5$, $S(O)_mR^5$, $S(O)_2NR^5R^6$, $C(S)NR^5R^6$, $CONR^5R^6$, $C(O)_nR^5$;

n is 0, 1 or 2;

m is 0, 1 or 2;

R^5 is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C_{1-8}alkoxy, aryl, heteroaryl, halogen, NO_2, CN, N_3, SCF_3, and CF_3;

R^6 is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C_{1-8}alkoxy, aryl, heteroaryl, halogen, NO_2, CN, N_3, SCF_3, and CF_3, or when R^1 and/or R^2 contains $S(O)_2NR^5R^6$, $CONR^5R^6$, or $C(S)NR^5R^6$, then R^5R^6 together with the nitrogen may form a heterocyclic ring; or

a pharmaceutically acceptable salt or solvate thereof.

2. A compound of formula (II)



(II)

wherein,

R^1 and R^2 are the same or are different and are C_{1-8} alkyl, C_{2-8} alkylene, C_{3-8} cycloalkyl, aryl, heteroaryl, heterocycloalkyl, C_{3-6} cycloalkylaryl, or heterocycloaryl; wherein said alkyl, alkylene, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkylaryl, or heterocycloaryl are unsubstituted or substituted by one or more groups selected from the group consisting of halogen, C_{1-8} alkyl, C_{1-8}alkoxy, C_{1-8}thioalkoxy, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, CF_3, SCF_3, $NHC(O)_nR^5$, $S(O)_mR^5$, $S(O)_2NR^5R^6$, $C(S)NR^5R^6$, $CONR^5R^6$, $C(O)_nR^5$;

n is 0, 1 or 2;

m is 0, 1 or 2;

R^5 is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C_{1-8}alkoxy, aryl, heteroaryl, halogen, NO_2, CN, N_3, SCF_3, and CF_3;

R^6 is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C_{1-8}alkoxy, aryl, heteroaryl, halogen, NO_2, CN, N_3, SCF_3, and CF_3, or when R^1 and/or R^2 contains $S(O)_2NR^5R^6$, $CONR^5R^6$, or $C(S)NR^5R^6$, then R^5R^6 together with the nitrogen may form a heterocyclic ring; or

a pharmaceutically acceptable salt or solvate thereof.

3. A compound of claim 1 wherein in formula (I) R^1, R^2 are the same or are different and are independently C_{3-6} alkyl, C_{3-6} alkylene, C_{3-8}cycloalkyl, C_{4-6} alkylaryl, C_{3-4}cycloalkylaryl, heterocycloaryl or heterocycloalkyl. Said C_{3-6} alkyl or heterocycloalkyl may be optionally substituted with $NHC(O)_nR^5$ or $C(O)_nR^5$ wherein n is 2 and R^5 is lower alkylaryl as herein defined wherein said lower alkylaryl may be optionally substituted with one or more groups selected from F, NO_2, or N_3.

4. A compound according to claim 3 wherein R^2 is n-butyl and R^1 is



5. A compound according to claim 3 which is

1,3-dicyclohexyl-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-5-(diaminomethylene)-3-(2-methylbutyl)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-5-(diaminomethylene)-3-(2,3-dihydro-1*H*-inden-2-yl)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-5-(diaminomethylene)-3-{4-[(trifluoromethyl)thio]phenyl}pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-5-(diaminomethylene)-3-mesitylpyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-5-(diaminomethylene)-3-(2,4-difluorophenyl)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-5-(diaminomethylene)-3-(2-fluorophenyl)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-3-(cyclohexylmethyl)-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-3-cycloheptyl-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-3-cyclooctyl-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-5-(diaminomethylene)-3-(3-phenylcyclopentyl)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-5-(diaminomethylene)-3-(5-phenylpentyl)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-[3-(benzyloxy)phenyl]-3-butyl-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

benzyl 3-[3-butyl-5-(diaminomethylene)-2,4,6-trioxotetrahydropyrimidin-1(2*H*)-yl]propylcarbamate,

4-nitrobenzyl 3-[3-butyl-5-(diaminomethylene)-2,4,6-trioxotetrahydropyrimidin-1(2*H*)-yl]propylcarbamate,

4-fluorobenzyl 3-[3-butyl-5-(diaminomethylene)-2,4,6-trioxotetrahydropyrimidin-1(2*H*)-yl]propylcarbamate,

4-($2\lambda^5$-triaza-1,2-dienyl)benzyl 3-[3-butyl-5-(diaminomethylene)-2,4,6-trioxotetrahydropyrimidin-1(2*H*)-yl]propylcarbamate,

1-but-3-enyl-3-cyclopentyl-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

4-($2\lambda^5$-triaza-1,2-dienyl)benzyl 4-[3-butyl-5-(diaminomethylene)-2,4,6-trioxotetrahydropyrimidin-1(2*H*)-yl]piperidine-1-carboxylate,

benzyl 3-[3-butyl-5-(diaminomethylene)-2,4,6-trioxotetrahydropyrimidin-1(2*H*)-yl]pyrrolidine-1-carboxylate,

1-butyl-5-(diaminomethylene)-3-(3,5-dimethylisoxazol-4-yl)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1,3-dibutyl-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-5-(diaminomethylene)-3-(4-phenylbutyl)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

benzyl 4-[3-butyl-5-(diaminomethylene)- 2,4,6-trioxotetrahydropyrimidin-1(2*H*)-yl]piperidine-1-carboxylate,

1-butyl-3-cyclopentyl-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-5-(diaminomethylene)-3-(2,3-dihydro-1*H*-inden-5-yl)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-(1,3-benzodioxol-5-yl)-3-butyl-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-3-cyclohexyl-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione

1,3-dibutyl-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-5-(diaminomethylene)-3-(4-phenylbutyl)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

benzyl 4-[3-butyl-5-(diaminomethylene)- 2,4,6-trioxotetrahydropyrimidin-1(2*H*)-yl]piperidine-1-carboxylate,

1-butyl-3-cyclopentyl-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-5-(diaminomethylene)-3-(2,3-dihydro-1*H*-inden-5-yl)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-(1,3-benzodioxol-5-yl)-3-butyl-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,

1-butyl-3-cyclohexyl-5-(diaminomethylene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione, or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 2 wherein in formula (II) R^1, R^2 are the same or are different and are independently C_{3-6} alkyl, C_{3-6} alkylene, C_{3-8}cycloalkyl, C_{4-6} alkylaryl, C_{3-4}cycloalkylaryl, heterocycloaryl or heterocycloalkyl. Said C_{3-6} alkyl or heterocycloalkyl may be optionally substituted with $NHC(O)_nR^5$ or $C(O)_nR^5$ wherein n is 2 and R^5 is lower alkylaryl as herein defined wherein said lower alkylaryl may be optionally substituted with one or more groups selected from F, NO_2, or N_3.

7 A compound according to claim 6 wherein R^2 is n-butyl and R^1 is



8. A compound according to claim 6 which is 6-amino-1,3-dibutyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbothioamide or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a compound of claim 1 in admixture with a pharmaceutically excipient.

10. A pharmaceutical composition comprising a compound of claim 2 in admixture with a pharmaceutically excipient.

11. A method for the prophylaxis of or treating osteoporosis in a mammal comprising administering a effective amount of a compound of claim 1 alone or in the form of a pharmaceutically acceptable excipient.

12. A method for the prophylaxis of or treating osteoporosis in a mammal comprising administering a effective amount of a compound of claim 2 alone or in the form of a pharmaceutically acceptable excipient.